Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > TH's website issues

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Apr 25, 2021 12:16pm

119 Views

Post# 33063450

RE:RE:RE:RE:RE:RE:RE:RE:RE:TH's website issues

AND THIS.....
Retail to the rescue? While the market had a tough time this week bumping up against the all-time highs, there was little in the way of serious selling, with the S&P making up its capital-gains-tax losses the very next session.
And the continued enthusiasm of retail investors could keep stocks on the front foot.
While "we’re sympathetic to calls for a correction here, retail money flows may well limit just how much of a drawdown we really see," DataTrek says.
DataTrek writes that the calls for a meaningful pullback need to acknowledge that retail investors are "very engaged with the current market" and "are 'better to buy', as old-time block traders used to say."
"Retail clients were the only buyers last week, while institutional and hedge fund clients sold," BofA strategists led by Jill Carey Hall wrote. "Retail clients have been buyers for the eighth straight week."

Retail investors could counter the much-anticipated correction: Alpha Tactics

https://seekingalpha.com/news/3685212-retail-investors-could-counter-the-much-anticipated-correction

longterm56 wrote: And at the right moment, casually mention to them that people on this board are aware of shareholders that hold > 30M shares ... seems ongoing conversations would be reasonable. -LT

scarlet1967 wrote:
I am not overly optimistic but since you have made the effort I would like to point out few things although you probably know:

1-You are not as good as they you are BETTER.

2-It seems you have already prepared your pitch with few requests, don’t let them bargain it is NOT a negotiation.

3-You can elaborate on your requests but most of the conversation should be about their responses.

4-Stay on topics don’t let them distract you from the purpose of the meeting.

5-If they can’t present solid plans to address the issues schedule another meeting as soon as possible so the company can respond with concrete solutions.

6-Leave the door open for future conversations so the company can interact with the shareholders on an ongoing basis.

5-Ideally everything should be in writing but since this is an informal meeting it would be a good idea if you could draft a summary of the meeting and email it back to the company for their review/approval before reporting back to the investors so there is an element of liability to the whole exercise.

Wino115 wrote: The only person I contacted was Paul. Although, I have noticed a ton of people with familiar names pinged my LinkedIn.

Bucknelly21 wrote:

great who contacted you wino?